journal article·2026-07

Cascade Nanozyme‐Catalyzed Tophi Dissolution and ROS Scavenging for Anti‐Inflammatory Therapy in Gouty Arthritis

Yi He, Juan Tan, Jianye Tan, Bo Liao, Shengwen Cheng, Pengcheng Xiao, Jiacheng Liu, Mingfei Dong, Ling He, Dingqun Bai, Gan Tian, Chen Zhao

Small· Volume 22· Issue 42
Publisher page

Abstract

ABSTRACT Tophi, inflammatory granulomas formed by intra‐articular monosodium urate (MSU) crystal deposition, remain challenging due to limited drug efficacy. While arthroscopic surgery removes tophi rapidly, mechanical debridement risks injury, and intraoperative MSU release can trigger severe oxidative stress induced inflammatory storm. To overcome this, we developed a cascade nanozyme, Ce‐MOF@Pt, enabling synergistic MSU clearance and ROS scavenging for MSU‐induced gouty arthritis. Pt nanoparticles possess oxidase (OXD)‐like activity, dissolving deeply embedded MSU crystals without mechanical injury and incidentally producing anti‐inflammatory allantoin. The Ce‐MOF matrix supports Pt and duplicates catalase (CAT)/superoxide dismutase (SOD)‐like activities, cascading H 2 O 2 decomposition and MSU‐induced ROS elimination. As UA degradation elevates the local pH values, its dominant activity intelligently switches from OXD‐like to SOD‐like mode, while the CAT‐like activity remains consistently high, ensuring continuous clearance of the H 2 O 2 byproduct and offering integrated anti‐oxidative therapy. In vitro, Ce‐MOF@Pt reduced inflammation via ROS scavenging and macrophage reprogramming. In vivo, it alleviated pain symptoms and joint inflammation in MSU‐induced gouty arthritis mice. Transcriptomics revealed Ce‐MOF@Pt mitigated the inflammatory storm by alleviating endoplasmic reticulum stress. This novel Ce‐MOF@Pt strategy offers minimally invasive tophi dissolution and prevents MSU‐induced inflammation, providing a promising therapeutic approach for tophi.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Gout, Hyperuricemia, Uric Acid

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Rehabilitation Medicine Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission The First Affiliated Hospital of Chongqing Medical University Chongqing P. R. China

Department of Orthopaedic Surgery Chongqing Municipal Health Commission Key Laboratory of Musculoskeletal Regeneration and Translational Medicine/Orthopaedic Research Laboratory The First Affiliated Hospital of Chongqing Medical University Chongqing P. R. China

Chongqing Institute of Advanced Pathology Jinfeng Laboratory Chongqing P. R. China

Chongqing Key Laboratory of Natural Product Synthesis and Drug Research Innovative Drug Research Center School of Pharmaceutical Sciences Chongqing University Chongqing P. R. China

Institute of Pathology and Southwest Cancer Center and Key Laboratory of Tumor Immunopathology Ministry of Education of China The First Affiliated Hospital Third Military Medical University (Army Medical University) Chongqing P. R. China

Funding

National Natural Science Foundation of China · China Postdoctoral Science Foundation

References (54)

Show source-provided references
1. 10.1016/j.semarthrit.2016.01.00510.1016/j.semarthrit.2016.01.005 ↗
2. 10.1016/j.semnephrol.2020.12.00110.1016/j.semnephrol.2020.12.001 ↗
3. 10.7326/annals‐24‐0395110.7326/annals‐24‐03951 ↗
4. 10.1007/s00264‐023‐06057‐510.1007/s00264‐023‐06057‐5 ↗
5. 10.1097/rhu.000000000000160810.1097/rhu.0000000000001608 ↗
6. 10.1016/j.ijscr.2024.11006610.1016/j.ijscr.2024.110066 ↗
7. 10.1136/annrheumdis‐2021‐22029510.1136/annrheumdis‐2021‐220295 ↗
8. 10.1136/ard‐2022‐22276410.1136/ard‐2022‐222764 ↗
9. 10.5435/jaaosglobal‐d‐22‐0021610.5435/jaaosglobal‐d‐22‐00216 ↗
10. 10.1016/j.arth.2023.01.06410.1016/j.arth.2023.01.064 ↗
11. 10.2147/jir.s32980010.2147/jir.s329800 ↗
12. 10.1001/jama.2022.1139010.1001/jama.2022.11390 ↗
13. 10.1136/annrheumdis‐2020‐21734210.1136/annrheumdis‐2020‐217342 ↗
14. 10.1016/j.biopha.2023.11595710.1016/j.biopha.2023.115957 ↗
15. 10.1016/j.ijbiomac.2022.03.14710.1016/j.ijbiomac.2022.03.147 ↗
16. 10.1038/s41584‐023‐01006‐310.1038/s41584‐023‐01006‐3 ↗
17. 10.1016/j.cell.2023.06.01010.1016/j.cell.2023.06.010 ↗
18. 10.1002/adma.20230412310.1002/adma.202304123 ↗
19. 10.1038/s41565‐024‐01715‐010.1038/s41565‐024‐01715‐0 ↗
20. 10.1002/smll.20180186510.1002/smll.201801865 ↗
21. 10.1007/s11426‐020‐9923‐910.1007/s11426‐020‐9923‐9 ↗
22. 10.1021/acs.nanolett.1c0445410.1021/acs.nanolett.1c04454 ↗
23. 10.1039/d0cs00920b10.1039/d0cs00920b ↗
24. 10.1002/adfm.20230756910.1002/adfm.202307569 ↗
25. 10.1039/c4cc10346g10.1039/c4cc10346g ↗
26. 10.1038/s41467‐021‐27945‐710.1038/s41467‐021‐27945‐7 ↗
27. 10.1111/j.2042‐7158.2012.01575.x10.1111/j.2042‐7158.2012.01575.x ↗
28. 10.1039/d3mh00717k10.1039/d3mh00717k ↗
29. 10.1073/pnas.231653712110.1073/pnas.2316537121 ↗
30. 10.1021/acs.nanolett.6b0351510.1021/acs.nanolett.6b03515 ↗
31. 10.1016/j.jcis.2022.04.13110.1016/j.jcis.2022.04.131 ↗
32. 10.1016/j.jcat.2022.05.02210.1016/j.jcat.2022.05.022 ↗
33. 10.1007/s00216‐021‐03620‐010.1007/s00216‐021‐03620‐0 ↗
34. 10.1002/adma.20210705410.1002/adma.202107054 ↗
35. 10.1002/adma.20241119410.1002/adma.202411194 ↗
36. 10.1002/ange.20250918310.1002/ange.202509183 ↗
37. 10.1016/j.lfs.2023.12153810.1016/j.lfs.2023.121538 ↗
38. 10.1111/j.1432‐1033.1974.tb03714.x10.1111/j.1432‐1033.1974.tb03714.x ↗
39. 10.1016/j.jconrel.2024.06.04210.1016/j.jconrel.2024.06.042 ↗
40. 10.1007/s40265‐023‐01944‐y10.1007/s40265‐023‐01944‐y ↗
41. 10.3390/biom1408097810.3390/biom14080978 ↗
42. 10.1016/j.freeradbiomed.2024.09.00910.1016/j.freeradbiomed.2024.09.009 ↗
43. 10.1023/a:101533160116910.1023/a:1015331601169 ↗
44. 10.1556/2060.105.2018.4.3010.1556/2060.105.2018.4.30 ↗
45. 10.5505/2017ichc.pp‐9010.5505/2017ichc.pp‐90 ↗
46. 10.1038/s41401‐021‐00749‐710.1038/s41401‐021‐00749‐7 ↗
47. 10.3389/fmed.2023.125521510.3389/fmed.2023.1255215 ↗
48. 10.1213/ane.000000000000688410.1213/ane.0000000000006884 ↗
49. 10.3389/fimmu.2023.129858310.3389/fimmu.2023.1298583 ↗
50. 10.1093/rheumatology/keae53310.1093/rheumatology/keae533 ↗
51. 10.1002/smll.20230874910.1002/smll.202308749 ↗
52. 10.1038/s41374‐022‐00798‐410.1038/s41374‐022‐00798‐4 ↗
53. 10.1038/s41392‐023‐01570‐w10.1038/s41392‐023‐01570‐w ↗
54. 10.1038/s41573‐021‐00320‐310.1038/s41573‐021‐00320‐3 ↗